Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)

Inclusion Criteria

• •Participants must identify as a woman
• •Participants must be age 18 or older
• •Participants must have a diagnosis of Stage 0, I, II, or III HR+ breast cancer
• •Participants must have started initial treatment with standard of care oral endocrine therapy (ET) (i.e., tamoxifen, anastrozole, exemestane, or letrozole) within 16 weeks of study registration.
• •Participants must have completed surgery for treatment of breast cancer at least 14 days prior to randomization.
• •Participants who received chemotherapy must have finished it at least 14 days prior to randomization.
• •Speak and read in English
• •Own an internet-enabled cell phone
• •Capable of using the electronic pill bottle
• •Concomitant radiotherapy is allowed. Concomitant maintenance targeted or biologic therapy (e.g., anti-HER2 therapy, osteoclast inhibitor therapy, CDK 4/6 inhibitor, ovarian function suppression medications) is allowed.